Lipum carries out a rights issue and enters into a framework agreement regarding pharmaceutical manufacturing

Lipum has carried out a rights issue of approximately SEK 80 million.

The net proceeds from the rights issue will mainly be used for the completion of the ongoing phase 1 clinical study of the drug lead candidate SOL-116, and for new production of SOL-116 for clinical phase 2 studies in accordance with a framework agreement for e.g. research, development and manufacturing of SOL-116 as an investigational medicinal product that Lipum has entered into with NorthX Biologics AB.

Lipum is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). Lipum’s shares are listed on Nasdaq First North Growth Market (LIPUM).

Lipum was represented by Mannheimer Swartling in connection with the rights issue and the entering into the framework agreement.